Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMBGI74)

Drug Name
ALX-0141 Drug Info
Synonyms Nanobody therapeutic (bone disease), Ablynx; Nanobody therapeutic (osteoporosis), Ablynx
Indication
Disease Entry ICD 11 Status REF
Osteoporosis FB83.0 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMBGI74

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Osteoclast differentiation factor (ODF) TT9E8HR TNF11_HUMAN Inhibitor [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Osteoclast differentiation factor (ODF) DTT TNFSF11 3.733 2.868 3.807 3.53
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

ICD Disease Classification 15 Disease of the musculoskeletal system/connective tissue
Disease Class ICD-11: FA20 Rheumatoid arthritis
The Studied Tissue Bone marrow
The Studied Disease Osteoporosis [ICD-11:FA20]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Osteoclast differentiation factor (ODF) DTT TNFSF11 6.42E-01 -0.16 -0.37
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031383)
2 Clinical pipeline report, company report or official report of Ablynx.